



**243-Day Revalor[®]-XS vs. Revalor-IS
Re-implanted with Revalor-S**

Trial protocol consisted of:

- Oklahoma trial location
- 1,225 head of cattle, 16 pens of 76 head per pen
- Revalor[®]-IS (trenbolone acetate and estradiol), and Revalor-XS given on day 1 of trial
- Revalor-S re-implanted on day 70
- Revalor-XS cattle were not removed from their pens on day 70
- No vaccine boosters were given

Table 1a. Feedyard performance of steers implanted with Revalor-IS on day 1 followed by Revalor-S on day 70 compared to steers implanted with Revalor-XS on day 1.

Item	Revalor-XS	Revalor-IS/ Revalor-S	CV	p-value
Pens	8	8		
Steers	612	613		
Days on feed	243	243		
Initial BW, lb	525	525	0.42	0.52
Live basis				
Final BW, lb ^a	1297	1294	0.58	0.47
DMI, lb/d	16.61	16.66	1.06	0.56
ADG, lb/d	3.19	3.17	0.99	0.48
F:G	5.22	5.26	1.6	0.39

^a 4% pencil shrink was applied to full weight.

^b Final adjusted shrunk weight adjusted to an average dressing percent of 63.5%

Table 1b. Feedyard performance of steers implanted with Revalor-IS on day 1 followed by Revalor-S on day 70 compared to steers implanted with Revalor-XS on day 1.

Item	Revalor-XS	Revalor-IS/ Revalor-S	CV	p-value
Carcass basis				
Final BW, lb ^b	1330	1324	0.64	0.23
ADG, lb/d	3.32	3.30	1.13	0.35
F:G	5.01	5.05	1.52	0.30
Health data				
BRD Mortality	1.63	2.12	97.9	0.61
BRD Morbidity	49.7	50.6	11.2	0.75
Buller %	1.14	0.97	99.5	0.75

^b Final adjusted shrunk weight adjusted to an average dressing percent of 63.5%.

Table 2. Carcass characteristics of steers implanted with Revalor-IS on day 1 followed by Revalor-S on day 70 compared to steers implanted with Revalor-XS on day 1.


Item	Revalor-XS	Revalor-IS/ Revalor-S	CV	p-value
Number of pens	8	8		
Steers	552	546		
Hot carcass weight, lb	844	841	0.64	0.22
Dressing percent	65.10	64.98	0.49	0.49
Ribeye area, sq. in.	13.57 ^a	13.40 ^b	1.08	0.04
Ribeye/cwt HCW	1.61	1.59	1.19	0.16
Marbling score ^e	437	428	2.55	0.14
Fat depth	0.57	0.55	5.39	0.13
Calculated YG	3.51	3.54	4.40	0.71
USDA Quality Grade, as percentage of total				
Prime	0.0	0.37	262.3	0.17
Upper Choice	3.01	3.76	77.1	0.58
Mid Choice	20.34 ^a	14.69 ^b	24.8	0.04
Total Choice	68.83 ^a	61.06 ^b	6.4	<0.01
Select	30.44 ^a	36.94 ^b	11.9	0.01
Standard	0.73 ^c	1.64 ^d	76.3	0.09
Dark cutter incidence, %	0.55	0.19	200.9	0.36
USDA Yield Grade, as percentage of total				
YG 1	6.84	4.84	61.5	0.30
YG 2	22.68 ^a	28.68 ^b	19.3	0.05
YG 3	43.78 ^a	35.76 ^b	11.5	<0.01
YG 4	17.96	20.27	21.9	0.30
YG 5	8.74	10.45	44.9	0.45

^{a,b} Treatments means are significantly different (P<0.05).

^{c,d} Treatments means are significantly different (P<0.10).


^e Slight = 300 to 399, Small = 400 to 499, etc..

USDA Quality Grade, as percentage of total



^{a,b} Treatments means are significantly different (P<0.05).

USDA Yield Grade, as percentage of total



^{a,b} Treatments means are significantly different (P<0.05).

Summary

Groups implanted with Revalor-XS and Revalor-IS followed by a re-implant of Revalor-S did not differ for any measurements of growth performance over the 243-day feeding period. Revalor-XS steers had a greater ($P<0.05$) percentage of carcasses grading average and total Choice and a lower percentage grading Select when compared with Revalor-IS followed by Revalor-S re-implant program. Steers implanted with Revalor-XS had greater ($P<0.05$) USDA Yield Grade 3 and fewer USDA Yield Grade 2 carcasses compared to Revalor-IS followed by Revalor-S re-implant program.

Conclusion

Revalor-XS had a greater percentage of Choice and fewer Select carcasses with equal growth performance when compared with a traditional implant/re-implant program of Revalor-IS/Revalor-S in steers fed for 243 days.

A withdrawal period has not been established for Revalor in pre-ruminating calves. Do not use in calves to be processed for veal. For complete information, refer to product label.

2 Giralda Farms • Madison, NJ 07940 • merck-animal-health-usa.com • 800-521-5767
Copyright © 2015 Intervet Inc., doing business as Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. 4/15 BV-51327-3-243d

